CureVac
Latest round
- Series D
Last raised
- Sep 2012
Total raised
- $139M
Investors
- 1
About CureVac
CureVac AG is a biotechnology firm specializing in mRNA-based therapeutics, founded in 2000 in Tubingen, Germany.CureVac specializes in developing innovative therapeutics based on messenger RNA (mRNA) technology. Its core products aim to create a new class of medicines targeting a range of diseases, including cancer and infectious diseases. By utilizing its proprietary RNA technology platform, the company enables the body to produce its own prophylactic and therapeutic proteins, enhancing the immune response. CureVac's products are primarily aimed at healthcare providers, pharmaceutical partners, and research institutions, with deployment in Europe, North America, and select Asian markets.16 mn. The company plans to introduce new mRNA-based therapeutics in the coming years, targeting the market for cancer and infectious disease treatments. Additionally, CureVac is looking to expand its market presence in North America and Asia by 2024, aiming to establish new partnerships and enhance its distribution capabilities.
Who invested in CureVac
1 investor across 2 rounds
See all investors in CureVac
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CureVac
Who invested in CureVac?
CureVac has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CureVac raised?
CureVac has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did CureVac last raise money?
CureVac's most recent round on record is a Series D, in Sep 2012.
What does CureVac do?
CureVac AG is a biotechnology firm specializing in mRNA-based therapeutics, founded in 2000 in Tubingen, Germany.
Where is CureVac headquartered?
CureVac is headquartered in Tubingen, Germany.
Which VCs invest in companies like CureVac?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at CureVac's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like CureVac? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.